Pegloticase

Pegloticase (trade name Krystexxa, formerly Puricase) is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals.

In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue. The European Medicines Agency (EMA) granted marketing authorization in January 2013 for treatment of disabling tophaceous gout. Pegloticase is the first drug approved for this indication. Krystexxa is currently marketed in the U.S. by Crealta Pharmaceuticals LLC.

单词	Pegloticase
释义	Pegloticase 英语百科 Pegloticase Pegloticase (trade name Krystexxa, formerly Puricase) is a drug for the treatment of severe, treatment-refractory, chronic gout, developed by Savient Pharmaceuticals. In September 2010, the FDA approved pegloticase for marketing in the United States after two clinical trials demonstrated the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue. The European Medicines Agency (EMA) granted marketing authorization in January 2013 for treatment of disabling tophaceous gout. Pegloticase is the first drug approved for this indication. Krystexxa is currently marketed in the U.S. by Crealta Pharmaceuticals LLC.
随便看	Haltmeier process halt mode halt number haltom Haltom City haltomcity Halton halt on halton city Halton Gill Halton Hills haltons halt phase halt point Halt problem halt problem mode halt processor mode Haltran Tablets Halts halt sign halt signal halt signal baton halt state halt switch halt transfer signal